RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor with an IC50 of 6.9 nM. It exhibits anti-necroptotic apoptosis activity by inhibiting RIPK1. In a TNF-alpha induced inflammatory in vivo model, a 10 mg/kg dose of RIPK1-IN-29 can protect mice from hypothermia and death. This compound is suitable for research in the field of inflammatory diseases.
Target:
RIP kinase
* VAT and and shipping costs not included. Errors and price changes excepted
